These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 21969887)

  • 1. The Role of Pharmacokinetics and Pharmacodynamics in Early Drug Development with reference to the Cyclin-dependent Kinase (Cdk) Inhibitor - Roscovitine.
    Hassan M; Sallam H; Hassan Z
    Sultan Qaboos Univ Med J; 2011 May; 11(2):165-78. PubMed ID: 21969887
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Age-dependent pharmacokinetics and effect of roscovitine on Cdk5 and Erk1/2 in the rat brain.
    Sallam H; Jimenez P; Song H; Vita M; Cedazo-Minguez A; Hassan M
    Pharmacol Res; 2008 Jul; 58(1):32-7. PubMed ID: 18588979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Roscovitine in cancer and other diseases.
    Cicenas J; Kalyan K; Sorokinas A; Stankunas E; Levy J; Meskinyte I; Stankevicius V; Kaupinis A; Valius M
    Ann Transl Med; 2015 Jun; 3(10):135. PubMed ID: 26207228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5.
    Meijer L; Borgne A; Mulner O; Chong JP; Blow JJ; Inagaki N; Inagaki M; Delcros JG; Moulinoux JP
    Eur J Biochem; 1997 Jan; 243(1-2):527-36. PubMed ID: 9030781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of the Cdk-inhibitor roscovitine on mouse hematopoietic progenitors in vivo and in vitro.
    Song H; Vita M; Sallam H; Tehranchi R; Nilsson C; Sidén A; Hassan Z
    Cancer Chemother Pharmacol; 2007 Nov; 60(6):841-9. PubMed ID: 17318617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Delayed treatment with systemic (S)-roscovitine provides neuroprotection and inhibits in vivo CDK5 activity increase in animal stroke models.
    Menn B; Bach S; Blevins TL; Campbell M; Meijer L; Timsit S
    PLoS One; 2010 Aug; 5(8):e12117. PubMed ID: 20711428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Cyclin-dependent kinase inhibitor CYC202 (R-roscovitine) inhibits retinoblastoma protein phosphorylation, causes loss of Cyclin D1, and activates the mitogen-activated protein kinase pathway.
    Whittaker SR; Walton MI; Garrett MD; Workman P
    Cancer Res; 2004 Jan; 64(1):262-72. PubMed ID: 14729633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-angiogenic effects of purine inhibitors of cyclin dependent kinases.
    Liebl J; Krystof V; Vereb G; Takács L; Strnad M; Pechan P; Havlicek L; Zatloukal M; Fürst R; Vollmar AM; Zahler S
    Angiogenesis; 2011 Sep; 14(3):281-91. PubMed ID: 21487803
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Roscovitine blocks leukocyte extravasation by inhibition of cyclin-dependent kinases 5 and 9.
    Berberich N; Uhl B; Joore J; Schmerwitz UK; Mayer BA; Reichel CA; Krombach F; Zahler S; Vollmar AM; Fürst R
    Br J Pharmacol; 2011 Jul; 163(5):1086-98. PubMed ID: 21391976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of roscovitine using novel high performance liquid chromatography and UV-detection method: pharmacokinetics of roscovitine in rat.
    Vita M; Meurling L; Pettersson T; Cruz-Sidén M; Sidén A; Hassan M
    J Pharm Biomed Anal; 2004 Feb; 34(2):425-31. PubMed ID: 15013157
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The cyclin-dependent kinase inhibitor roscovitine inhibits kinase activity, cell proliferation, multicellular development, and Cdk5 nuclear translocation in Dictyostelium discoideum.
    Huber RJ; O'Day DH
    J Cell Biochem; 2012 Mar; 113(3):868-76. PubMed ID: 22234985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of CDKS by roscovitine suppressed LPS-induced *NO production through inhibiting NFkappaB activation and BH4 biosynthesis in macrophages.
    Du J; Wei N; Guan T; Xu H; An J; Pritchard KA; Shi Y
    Am J Physiol Cell Physiol; 2009 Sep; 297(3):C742-9. PubMed ID: 19553566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine.
    De Azevedo WF; Leclerc S; Meijer L; Havlicek L; Strnad M; Kim SH
    Eur J Biochem; 1997 Jan; 243(1-2):518-26. PubMed ID: 9030780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CDK inhibitors induce mitochondria-mediated apoptosis through the activation of polyamine catabolic pathway in LNCaP, DU145 and PC3 prostate cancer cells.
    Arisan ED; Obakan P; Coker-Gurkan A; Calcabrini A; Agostinelli E; Unsal NP
    Curr Pharm Des; 2014; 20(2):180-8. PubMed ID: 23701543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Roscovitine inhibits activation of promoters in herpes simplex virus type 1 genomes independently of promoter-specific factors.
    Diwan P; Lacasse JJ; Schang LM
    J Virol; 2004 Sep; 78(17):9352-65. PubMed ID: 15308730
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pyrazolo[1,5-a]-1,3,5-triazine as a purine bioisostere: access to potent cyclin-dependent kinase inhibitor (R)-roscovitine analogue.
    Popowycz F; Fournet G; Schneider C; Bettayeb K; Ferandin Y; Lamigeon C; Tirado OM; Mateo-Lozano S; Notario V; Colas P; Bernard P; Meijer L; Joseph B
    J Med Chem; 2009 Feb; 52(3):655-63. PubMed ID: 19128055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interplay between the p53 tumor suppressor protein family and Cdk5: novel therapeutic approaches for the treatment of neurodegenerative diseases using selective Cdk inhibitors.
    Schmid G; Strosznajder JB; Wesierska-Gadek J
    Mol Neurobiol; 2006 Aug; 34(1):27-50. PubMed ID: 17003520
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p35, the neuronal-specific activator of cyclin-dependent kinase 5 (Cdk5) is degraded by the ubiquitin-proteasome pathway.
    Patrick GN; Zhou P; Kwon YT; Howley PM; Tsai LH
    J Biol Chem; 1998 Sep; 273(37):24057-64. PubMed ID: 9727024
    [TBL] [Abstract][Full Text] [Related]  

  • 19. N-&-N, a new class of cell death-inducing kinase inhibitors derived from the purine roscovitine.
    Bettayeb K; Sallam H; Ferandin Y; Popowycz F; Fournet G; Hassan M; Echalier A; Bernard P; Endicott J; Joseph B; Meijer L
    Mol Cancer Ther; 2008 Sep; 7(9):2713-24. PubMed ID: 18790752
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cell cycle arrest induced in human breast cancer cells by cyclin-dependent kinase inhibitors: a comparison of the effects exerted by roscovitine and olomoucine.
    Wesierska-Gadek J; Gueorguieva M; Wojciechowski J; Horky M
    Pol J Pharmacol; 2004; 56(5):635-41. PubMed ID: 15591654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.